Artiva Biotherapeutics, Inc.

ARTV Healthcare Biotechnology

Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023. In the quarter to June 2026, EPS grew 27.6% and free cash flow grew 13.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.85 0.21 −3.47%
Market cap
$296.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
n/a
Altman Z
1.27
Beneish M
−22.63
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23
Total current assets
112.67 188.63 79.82
Total non-current assets
18.27 20.95 25.29
Total Assets
130.94 209.58 105.11
Total current liabilities
13.09 12.25 12.23
Total non-current liabilities
7.88 10.69 254.90
Total liabilities
20.97 22.94 267.13
Common Equity (Total)
109.97 186.64 (162.01)
Shareholders Equity (Total)
109.97 186.64 (162.01)
Total Debt
— 0.04 —

Show all line items

In millions of $ except per-share values · columns are period end dates